Standard BioTools Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Standard BioTools Inc. (LAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $10.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2023-03-14
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $2.00K.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-06-30 was $1.00K.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-03-31 was $7.00K.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $10.00K, a 60.00% decline from fiscal 2021.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $25.00K, a 93.04% decline from fiscal 2020.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $359.00K, a 70.03% decline from fiscal 2019.
- Standard BioTools Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $1.20M, a 1379.01% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $2.00K derived: sum of 2 quarters · filed 2023-03-14 | $3.00K derived: sum of 3 quarters · filed 2023-03-14 | $10.00K 10-K · filed 2023-03-14 | |
| 2022-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $3.00K derived: sum of 2 quarters · filed 2022-11-09 | $10.00K 10-Q · filed 2022-11-09 | $13.00K derived: sum of 4 quarters · filed 2023-03-14 | |
| 2022-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $8.00K 10-Q · filed 2022-08-09 | $11.00K derived: sum of 3 quarters · filed 2023-03-14 | ||
| 2022-03-31 | $7.00K 10-Q · filed 2022-05-09 | $10.00K derived: sum of 2 quarters · filed 2023-03-14 | |||
| 2021-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $25.00K 10-K · filed 2023-03-14 | |||
| 2021-09-30 | $22.00K 10-Q · filed 2021-11-09 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $7.00K derived: sum of 2 quarters · filed 2022-03-08 | |||
| 2020-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $359.00K 10-K · filed 2022-03-08 | |||
| 2020-09-30 | $352.00K 10-Q · filed 2020-11-09 | ||||
| 2019-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $51.00K derived: sum of 2 quarters · filed 2022-03-08 | $944.00K derived: sum of 3 quarters · filed 2022-03-08 | $1.20M 10-K · filed 2022-03-08 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $893.00K derived: sum of 2 quarters · filed 2019-11-08 | $1.15M 10-Q · filed 2019-11-08 | ||
| 2019-06-30 | $893.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $1.15M 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $254.00K 10-Q · filed 2019-05-07 | ||||
| 2018-12-31 | $81.00K 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $42.00K 10-K · filed 2020-02-27 | $100.00K 10-K · filed 2018-03-08 | |||
| 2016-12-31 | $310.00K 10-K · filed 2019-03-18 | $300.00K 10-K · filed 2017-03-03 | |||
| 2015-12-31 | $13.70M 10-K · filed 2018-03-08 | ||||
| 2014-12-31 | $12.80M 10-K · filed 2017-03-03 | ||||
| 2013-12-31 | $20.80M 10-K · filed 2016-02-29 | ||||
| 2012-12-31 | $5.50M 10-K · filed 2015-02-26 | ||||
| 2011-12-31 | $3.10M 10-K · filed 2014-03-12 | ||||
| 2010-12-31 | $100.00K 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |